Biotech Funds: Enter With Care
Investors in biotech have the potential to reap tremendous rewards, but at the same time, the risk can be enormous -- sometimes in the same stock.
For example, an investor in Neurocrine Biosciences (NBIX) could have gotten into the stock below $5 in 1999. Neurocrine topped out at $73 in March of this year.
However, after the FDA failed to approve its insomnia treatment Indiplon and after partner Pfizer (PFE) walked away from the drug, Neurocrine's stock crashed, closing Wednesday at $9.23.
Mutual funds have long been a preferred method for investors to diversify their holdings, but there aren't too many biotech-oriented options. I found 10 funds that invest most of their assets in biotech. Several others have significant exposure to the sector but also invest heavily in medical devices, pharmaceuticals and health care stocks.Christopher Davis, a fund analyst with Morningstar, suggests one of these broader health care funds for investors who want exposure to biotech. That way, a negative ruling by the FDA on a biotech stock doesn't wreck your portfolio. He points to (PRHSX) T. Rowe Price Health Sciences as one of his favorites. Of the fund's portfolio, 43% is invested in biotech stocks. "It has a more aggressive approach and looks for faster-growing companies than some of its competitors," he said. As of March 31, four of its top five holdings were biotech -- Gilead Sciences (GILD), Amgen (AMGN), Genentech (DNA) and Cephalon (CEPH). That's pretty much what you'll find in most biotech funds, and ETFs for that matter, says Davis, and that is why he recommends avoiding the sector-heavy funds to begin with. "Chances are, you have exposure to these companies through your other mutual funds," he says. "Every large-cap growth fund owns Amgen and Genentech." Plus, the mutual funds in the sector tend to be expensive. The ones that aren't appear to have managers with less-than-stellar track records.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV